CRCU

Chemical Research in Chinese Universities ›› 2012, Vol. 28 ›› Issue (4): 656-661.

• Articles • Previous Articles     Next Articles

Anti-tumor Activity of Biodegradable Polymer-paclitaxel Conjugated Micelle Against Mice U14 Cervical Cancers

CHEN Feng1, DONG Dan1, FU Yan1, ZHENG Yong-hui2, LIU Shi2, CHANG Ming-xin3, JING Xia-bin 2   

  1. 1. The First Hospital of Jilin University, Changchun 130021, P. R. China;
    2. State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P. R. China;
    3. Affiliated Hospital to Changchun University of Chinese Medicine, Changchun 130021, P. R. China
  • Received:2012-03-29 Revised:2012-05-22 Online:2012-07-25 Published:2012-07-25
  • Supported by:

    Supported by the National Natural Science Foundation of China(Nos.20674084, 21004062, 51103148), the National Basic Research Program of China(No.2009CB930102) and the National High-Tech Research and Development Program of China(No. 2007AA03Z535).

PDF (PC)

Cited

50

Abstract: Two kinds of paclitaxel(PTX) conjugate micelles, of which one contained 25%(mass fraction) PTX [M(PTX)] and the other contained 22.5%(mass fraction) of PTX and 1.4%(mass fraction) of folate(FA)[FA-M(PTX)], were prepared for cell apoptosis and anti-tumor activity evaluation on U14 cervical cancer mouse models in comparison with 0.9%(mass fraction) saline(control) and equivalent Taxol. Seven days after tail intravenous injection of the drugs, the mice were sacrificed to measure the tumor masses. The average tumor masses were 4.26, 2.89, 2.63, and 2.17 g for the control, Taxol, M(PTX) and FA-M(PTX) groups, respectively. The inhibition rates of tumor growth calculated for the three drug groups were 32%, 38% and 49%, respectively. Flow cytometry(FC) analysis and termi- nal deoxynucleotidyl transferase(TdT)-mediated deoxyuridine triphosphate(dUTP) nick end labeling(TUNEL) assay were conducted on the cancer tissues. The cell apoptosis rates based on the FC data and the TUNEL data were 20%, 31%, 37%, 42%, and 10%, 22%, 26%, 34%, respectively, both showing statistically significant differences(P<0.05) between three drug groups and the control group, and between the FA-M(PTX) group and the other two drug groups. In conclusion, the composite FA-M(PTX) micelles can be used for U14 cervical cancer treatment.

Key words: Cervical cancer, Polymer-drug conjugate, Paclitaxel, Folic acid, Targeted drug delivery